Myelodysplastic syndrome associated with olaparib
10.3760/cma.j.cn114015-20221103-01023
- VernacularTitle:奥拉帕利相关骨髓增生异常综合征
- Author:
Hairong YAO
1
;
Shikai LIU
1
Author Information
1. 沧州市中心医院妇三科，沧州 061000
- Publication Type:Journal Article
- Keywords:
Ovarian neoplasms;
Myelodysplastic syndrome;
Poly ADP-ribose polymerase inhibitors;
Olaparib
- From:
Adverse Drug Reactions Journal
2023;25(11):702-704
- CountryChina
- Language:Chinese
-
Abstract:
A 58-year-old female patient underwent ovarian cancer tumor cell reduction surgery for advanced ovarian serous carcinoma in stage ⅣB for more than 3 years and received chemotherapy with paclitaxel and carboplatin regimen for a total of 6 cycles and chemotherapy with doxorubicin liposome and carboplatin regimen for a total of 6 cycles successively. After that, olaparib 300 mg was administered twice daily orally for maintenance treatment. Twenty-five days later, due to the occurrence of grade Ⅱ bone marrow suppression in the patient, the dose of olaparib was reduced to 150 mg in the morning and 300 mg in the evening. After 13 months of olaparib treatment, the patient developed pancytopenia, with the lowest platelet count of 2×10 9/L. Olaparib was stopped immediately.The symptomatic and supportive treatments such as infusion of suspended red blood cells and fresh platelets, elevation of white blood cells,iron replenishment, and platelet elevation were given, but the efficacy was not obvious. Bone marrow flow cytometry detection suggested a high possibility of myelodysplastic syndrome. After discontinuing olaparib for 47 days, the patient died of circulatory failure due to massive abdominal and pelvic bleeding and hemorrhagic shock.
